Fig. 6: Romidepsin enhances the sensitivity of HCC to PARP inhibitors.
a Dose-response curves for Olaparib in HCC cell lines following treatment with IC20 of Romidepsin (n = 4 biologically independent samples). b Synergistic dose-response curves for HCCLM3 cells treated with varying concentrations of Olaparib and Romidepsin (n = 4 biologically independent samples). c Combination index (CI) versus fraction affected for Olaparib and Romidepsin in HCCLM3 cells, derived from data in b (n = 4 biologically independent samples). d HCCLM3 tumors were dissected from the nude mice treated with vehicle, Olaparib, Romidepsin, or both (n = 5/group). e Quantitative analysis of tumor (n = 5) volume from d. f As d, but for Hepa1-6 tumor-bearing C57/BL6 mice (n = 6/group). g Quantitative analysis of tumor (n = 6) volume from f. h Schematic diagram of murine MYC-driven HCCs. After mating of H11LSL-Myc mice harboring a CAG promoter-loxp-STOP-loxp-Myc-polyA conditional overexpression structure at the H11 locus with Alb-cre mice for two months, the spontaneous development of HCC was observed. Subsequently, these murine HCCs were transplanted into the subcutaneous tissues for treatment. i As d, but for MYC-driven HCC tumor-bearing C57/BL6 mice (n = 5/group). j Quantitative analysis of tumor (n = 5) volume from i. k Schematic diagram of human HCC PDX. l As d, but for HCC PDX tumor-bearing NSG mice (n = 8/group). m Quantitative analysis of tumor (n = 8) volume from l. Mean values ± SEM. Two-sided t-tests. Figures h and k created with BioRender.com, released under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International license. Source data are provided as a Source Data file.
